Literature DB >> 9496982

Acetaminophen and other risk factors for excessive warfarin anticoagulation.

E M Hylek1, H Heiman, S J Skates, M A Sheehan, D E Singer.   

Abstract

CONTEXT: Warfarin is highly effective in preventing thromboembolism, but increases the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0. Identifying causes of excessive anticoagulation in clinical practice could help target patients at risk for elevated INRs.
OBJECTIVE: To determine causes of INRs greater than 6.0 in a clinical practice setting.
DESIGN: Case-control study.
SETTING: Outpatient anticoagulant therapy unit. PATIENTS: Outpatients followed up prospectively from April 1995 to March 1996 who had been taking warfarin for more than 1 month, had a target INR of 2.0 to 3.0, and were able to be interviewed within 24 hours of their reported INR. Case patients had INRs greater than 6.0; controls were randomly selected from patients having INRs between 1.7 and 3.3. MAIN OUTCOME MEASURES: Factors associated with INRs greater than 6.0, including medication use, recent diet, illness, alcohol consumption, and actual warfarin use.
RESULTS: A total of 93 cases and 196 controls were interviewed; they did not differ in age, indication for warfarin, length of therapy, warfarin dose, number of prescription medications, or previous INR or long-term INR variability. Acetaminophen ingestion was independently associated in a dose-dependent manner with having an INR greater than 6.0 (P for trend <.001). For the highest-dose category of acetaminophen intake, 9100 mg/wk or more, the odds of having an INR greater than 6.0 were increased 10-fold (95% confidence interval [CI], 2.6-37.9). Other factors independently associated with an INR greater than 6.0 were new medication known to potentiate warfarin (odds ratio [OR], 8.5; 95% CI, 2.9-24.7), advanced malignancy (OR, 16.4; 95% CI, 2.4-111.0), recent diarrheal illness (OR, 3.5; 95% CI,1.4-8.6), decreased oral intake (OR, 3.6; 95% CI, 1.3-9.7), and taking more warfarin than prescribed (OR, 8.1; 95% CI, 2.2-30.0). Higher vitamin K intake (OR, 0.7; 95% CI, 0.5-0.9) and habitual alcohol consumption of from 1 drink every other day to 2 drinks a day (OR, 0.2; 95% CI, 0.1-0.7) were associated with decreased risk.
CONCLUSIONS: These data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting. Several other clinically important risk factors were identified. Increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496982     DOI: 10.1001/jama.279.9.657

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  53 in total

Review 1.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Key questions concerning paracetamol and NSAIDs for osteoarthritis.

Authors:  P Courtney; M Doherty
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

3.  Drug interactions-information, education, and the British National Formulary.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

4.  Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients.

Authors:  Chadwick K Mellen; Marjorie Ford; Joseph P Rindone
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 5.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 6.  Managing anticoagulant related coagulopathy.

Authors:  Amir K Jaffer
Journal:  J Thromb Thrombolysis       Date:  2007-10-17       Impact factor: 2.300

Review 7.  Patterns and perceptions of complementary/alternative medicine among paediatricians and patients' mothers: a review of the literature.

Authors:  Laura Cuzzolin; Silvana Zaffani; Vitalia Murgia; Michele Gangemi; Giorgio Meneghelli; Giampietro Chiamenti; Giuseppina Benoni
Journal:  Eur J Pediatr       Date:  2003-09-26       Impact factor: 3.183

8.  Paracetamol: a haemorrhagic risk factor in patients on warfarin.

Authors:  I Mahé; N Bertrand; L Drouet; G Simoneau; E Mazoyer; C Bal dit Sollier; C Caulin; J F Bergmann
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

Review 9.  Alcohol intake and noncoronary cardiovascular diseases.

Authors:  Kenneth Mukamal
Journal:  Ann Epidemiol       Date:  2007-05       Impact factor: 3.797

10.  Effectiveness of warfarin among patients with cancer.

Authors:  Adam J Rose; Jeff P Sharman; Al Ozonoff; Lori E Henault; Elaine M Hylek
Journal:  J Gen Intern Med       Date:  2007-05-03       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.